- Home
- BSRR vs RIGL Comparison
BSRR vs RIGL Comparison
Compare BSRR & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BSRR | RIGL |
|---|---|---|
| Founded | 1977 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 532.1M | 564.7M |
| IPO Year | 2001 | 2000 |
Fundamental Metrics
Financial Performance| Metric | BSRR | RIGL |
|---|---|---|
| Price | $39.85 | $45.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $37.00 | ★ $45.67 |
| AVG Volume (30 Days) | 56.4K | ★ 276.9K |
| Earning Date | 04-27-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.93% | N/A |
| EPS Growth | 10.28 | ★ 1867.68 |
| EPS | ★ 1.72 | 1.32 |
| Revenue | N/A | ★ $294,282,000.00 |
| Revenue This Year | $11.74 | N/A |
| Revenue Next Year | $3.63 | $12.75 |
| P/E Ratio | ★ $23.05 | $34.17 |
| Revenue Growth | N/A | ★ 64.15 |
| 52 Week Low | $26.49 | $24.84 |
| 52 Week High | $43.13 | $52.24 |
Technical Indicators
Market Signals| Indicator | BSRR | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 43.14 | 63.01 |
| Support Level | $38.43 | $40.05 |
| Resistance Level | $41.74 | $49.10 |
| Average True Range (ATR) | 1.01 | 2.22 |
| MACD | -0.08 | 0.44 |
| Stochastic Oscillator | 12.94 | 75.44 |
Price Performance
Historical ComparisonAbout BSRR Sierra Bancorp
Sierra Bancorp is a California-based bank holding company, which offers a range of retail and commercial banking services. It offers a wide range of deposit products and services for individuals and businesses including checking accounts, savings accounts, money market demand accounts, time deposits, retirement accounts, and sweep accounts. The company's lending activities cover real estate, commercial (including small business), mortgage warehouse, agricultural and consumer loans, and also offers commercial construction loans and multifamily and agricultural credit facilities among other types of real estate loans.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.